STAT Research - CABA
Somos un Centro de investigación Clínica de carácter médico dedicada hace más de 20 años a proporcionar servicios de apoyo a instituciones de salud, biotecnología y a la industria farmacéutica. Fundado por el Dr. Conrado Estol. Nuestra sede está ubicada en CABA, Argentina. Contamos con un equipo con sólidos antecedentes académicos y de investigación, altamente calificado, especializado en 10 áreas terapéuticas. Hemos participado en más de 100 ensayos clínicos.Av. Callao 875, CABA, Buenos Aires
Select an option
I am a doctor
I am a sponsor
Specializations
Alopecia
Cardiovascular
Colangitis biliar primaria
Dermatitis atópica
Diabetes
Enfermedad cardiovascular
Esclerosis múltiple
Esclerosis múltiple primaria progresiva
EPOC
Insuficiencia cardíaca
Lupus eritematoso cutáneo
Lupus eritematoso discoide
Miastenia gravis
Neurodermatitis
Taquicardia supraventricular paroxística
Urticaria
Our team
Authorities
Director médico e Investigador PrincipalConrado Jose Estol
Site ManagerMaria Celina Ocampo
Medical staff
Lucas Gutnisky
Patricia Gonzalez Colaso
Constanza García Méndez
Analía De Navarrete
Abel Bordón
Fernando Botto
Augusto Lavalle Cobo
Tania Zarowsky
Marcos Suffriti
Jorge Alejandro Brigante
María Eugenia Linares
Verónica Lacal Ridilenir
Mariano Gabriel Marini
José Máximo Barros
Open studies
Arterial hypertension
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. - AstraZenecaSee more
Arthritis
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis - PSUMMIT-Jr - Janssen Research & Development, LLCSee more
Cardiovascular disease
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and CompanySee more
Dermatitis
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis - ATLANTIS - SanofiSee more
Diabetes
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) - Eli Lilly and CompanySee more
Elevated Lipoprotein A
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and CompanySee more
Epilepsies
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) - Xenon Pharmaceuticals Inc.See more
Head and neck cancer
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma - JADE - GlaxoSmithKlineSee more
Hypertriglyceridemia
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia - ENTRUST - 89bio, Inc.See more
Interstitial Lung Disease
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease - BEconneCTD-ILD - GlaxoSmithKlineSee more
Lupus
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus - TOPAZ-2 - BiogenSee more
Multiple sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) - REMODEL-1 - Novartis PharmaceuticalsSee more
Multiple Sclerosis
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis - FREXALT - SanofiSee more
Obesity
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and CompanySee more
Renal disease
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. - AstraZenecaSee more
Seizure
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures - X-ACKT - Xenon Pharmaceuticals Inc.See more
Urticaria
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension. - Novartis PharmaceuticalsSee more
